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Clear cell RCC was more prevalent among Hispanics (88.9% vs 85%, p
<0.004). Hispanics were found to have lower AJCC stage at diagnosis
(I/II vs III/IV) than NHW (67.4% vs 62.2%, p <0.044). Overall Hispanics
were found to have a greater incidence of comorbidities such as chronic
kidney disease (2.6% vs 0.7%, p <0.0001), and diabetes (23.8% vs
15.9%, p <0.001), but still were more inclined to receive surgery (84.2%
vs 77.9%, p <0.004). On multivariate analysis, the presence of me-
tastases (P <0.001), nodal involvement (P <0.001), increased tumor
size (P <0.001), non-surgical management (P <0.001), increasing age
(P <0.001), and Hispanic race (P <0.023) were independent predictors
of worse outcome.
CONCLUSIONS: Even within a healthcare system with similar
access to care, Hispanics with RCC were younger, had greater
comorbidities, and more frequently had clear cell RCC. Despite a lower
AJCC stage and increase receipt of surgery, Hispanic ethnicity was an
independent predictor of worse outcome. Further work is necessary to
confirm this health disparity in other large datasets.
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INTRODUCTION AND OBJECTIVES: The decision to perform
a staging chest-CT scan [CCT] remains an empirical process, due to
the lack of predictive models assessing the risk of pulmonary metas-
tasis at kidney cancer [RCC] diagnosis. The aim of the study was to
predict the risk of pulmonary metastasis at CCT in order to provide
objective criteria for patient selection.
METHODS: An assessment of 1,946 patients surgically treated
for RCC and collected in a prospective institutional database was per-
formed. The outcome of the study was the presence of pulmonary
metastasis at staging CCT. Patients without a pre-operative CCT scan
but with a negative post-operative CCT scan were considered negative
at staging by-definition. A multivariable logistic regression model was
fitted to predict positive CCT scan. Predictors consisted of preoperative
haemoglobin/platelet ratio, clinical tumour stage [cT], clinical nodal
stage [cN] and presence of systemic symptoms. A 2000-sample boot-
strap validation was used to estimate H-index. Decision curve analysis
was used to asses the performance of the model in clinical-decision
making.
RESULTS: Overall, CCT scan resulted negative in 1827 (94%)
patients and positive in 119 patients (6%). Preoperative haemoglobin/
platelet ratio was associated with higher risk of positive CCT (Odds
Ratio [OR] 1.04; 95% Confidence Interval [CI] 1.02-1.06; p<0.0001).
Moreover, cT1b (OR 2.69; CI 1.16-6.22; p¼0.02), cT2 (OR 9.13; CI
4.13-20.18; p<0.0001) and cT3-cT4 (OR 15.41; CI 6.73-35.25;
p<0.0001) resulted associated with higher risk of positive CCT relative
to cT1a patients. Similarly, cN1 (OR 3.21; CI 2.05-5.01; p<0.0001) and
presence of systemic symptoms (OR 3.88; CI 2.39-6.31; p<0.0001)
were also associated with higher risk of positive CCT. Following a 2000-
sample bootstrap validation, H-index of the proposed model resulted
0.88 (CI 0.85-0.92). At decision curve analysis, the net benefit of the
proposed model was superior than the treat-all and treat-none
strategies.
CONCLUSIONS: Based on the proposed model, it is possible
to estimate the risk of positive CCT at kidney cancer staging using pre-
operative characteristics with optimal predictive accuracy. At decision
curve analysis, the net benefit of the proposed model was superior than
the treat-all and treat-none strategies. If CCT is planned only when the
risk of a positive results is >1% a negative CCT is spared in 37% of the
population and a positive CCT is missed in <1% of the population only.These figures support the use of the proposed model in clinical-decision
making.
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INTRODUCTION AND OBJECTIVES: Epithelioid angiomyoli-
poma (AML) is the subtype of AML, which has malignancy potential. We
evaluated the clinical characteristics associated with epithelioid AML
and the prognosis of epithelioid AML.
METHODS: Medical records of 231 patients consist of 204
patients with epithelioid AML and 27 patients with conventional AML
were reviewed. Computed tomography (CT) was performed in all pa-
tients before pathological confirmation of the disease. Tumor size and
Hounsfiled unit (HU) were measured on pre-contrast and arterial phase
of CT. Pathologic specimens were reviewed by pathologists who are
specialized in urologic pathology. Variables associated with epithelioid
AML were assessed using multivariate analysis.
RESULTS: Patients with epithelioid AML were younger (41.2
years vs. 49.1 years, p ¼ 0.001) than patients with conventional AML.
Male patients were more common in patients with epithelioid AML (56%
vs. 29%, p ¼ 0.005). Tumor size was larger in patients with epithelioid
AML compared to conventional AML (7.5cm vs. 4.2cm, p < 0.001).
Difference in HU between pre-contrast and arterial phase was signifi-
cant lower in epithelioid AML group (46.6 vs. 65.9 HU, p¼0.022). In
multivariable logistic regression analysis, younger age (p ¼ 0.024) and
male gender (p ¼ 0.024) were significantly associated with epithelioid
AML. Among 27 patients with epithelioid AML, distant metastasis was
observed in 8 (29.7%) patients and these patients had larger tumor
compared with the other 19 patients (10.8cm vs. 6.1cm, p ¼ 0.014).
Three patients with metastasis were expired in 10 days, 47 months and
118 months after the diagnosis of the disease.
CONCLUSIONS: Patients with epithelioid AML should be
carefully followed-up because of malignancy potential. We should not
overlook the probability of epithelioid AML, especially in young male
patients with larger tumor size.
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INTRODUCTION AND OBJECTIVES: Few models predicting
the presence of lymph node invasion (LNI) in patients with renal cell
carcinoma (RCC) are available. In this study, we tested the ability of LNI
risk estimation relying on clinically attainable variables.
METHODS: Between 1987 and 2014, 4,948 RCC patients
treated with either partial or radical nephrectomy within a multi-institu-
tional cohort were identified. Multivariable logistic regression analyses
Vol. 195, No. 4S, Supplement, Monday, May 9, 2016 THE JOURNAL OF UROLOGY e963were used to test the accuracy of all the available clinical characteristics
in predicting LNI. A nomogram predicting the probability of LNI was
constructed using the logistic regression-derived coefficients. Log
transformation was applied for clinical tumor size after non-linearity
analysis. Calibration plot and leave-one-out cross validation (LOOCV)
were used for internal validation.
RESULTS: Overall, 204 patients (4.1%) had LNI. In multivari-
able analyses, symptoms at diagnosis (OR: 1.64; p<0.006), clinical
tumor size (OR: 1.11; p<0.001), non-organ confined (OR: 2.65;
p<0.001), clinical LNI (OR: 15.6; p<0.001) and presence of clinical
metastases (OR: 2.4; p<0.001) were each significantly associated with
the risk of LNI. The curve depicting the relationship between predicted
and observed LNI closely approximates the ideal predictions, which
indicates excellent calibration. In LOOCV, the C-index of our model was
92.1%. Using a 5% nomogram cut-off, 4.346 of 4.948 patients (87.8%)
would be spared lymph-node dissection (LND) and LNI would be
missed in 39 patients (0.9%, 19.1% of all LNI). The sensitivity, speci-
ficity, and negative predictive value associated with the 5% cut-off were
80.9%, 90.8%, and 99.1%, respectively. To minimize the number of LNI
patients missed, a 1% nomogram cut-off may be considered, allowing to
spare 57% of LND and missing only 7 LNI patients (0.1%, 3% of all LNI
cases).
CONCLUSIONS: We developed and internally validated a tool
capable of highly accurately predicting LNI in RCC patients. This ac-
curate tool could be useful for patient counseling and risk stratification at
medical decision-making. Based on our model, patients with a LNI risk
< 1% may be safely spared LND. Given the number of LNI cases
missed when higher cutoffs were considered, further studies aimed at
identifying accurate biomarkers of hidden LNI are urgently needed,
especially in low-stage disease.
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INTRODUCTION AND OBJECTIVES: Proteinuria is has
recently been included into Kidney Disease: Improving Global Out-
comes (KDIGO) risk stratification of chronic kidney disease (CKD) in the
general population. However, the importance of proteinuria in patients
with renal cancer has not been well studied. We sought to evaluate the
prognostic impact of preoperative proteinuria on overall survival (OS)
and stability of renal function (SRF) for patients managed with renal
cancer surgery.
METHODS: From 1999-2008, 977 patients underwent renal
cancer surgery with recorded preoperative estimated glomerular
filtration rate (eGFR) based on CKD epidemiology collaboration
(CKD-EPI) equations (G1:>90ml/min/1.73m2; G2:60-89; G3a:45-59;
G3b:30-44; G4:15-29; G5<15) and proteinuria status based on
dipstick (ANEG:negative/trace or APOS>30mg/dL). Median follow-up
was 8.7(7.0-10.7) years. OS and SRF (avoidance of 50% or greater
GFR decline and avoidance of dialysis) were analyzed using Kaplan-
Meier. Multivariable Cox regression evaluated for independent pre-
dictors for both outcomes.
RESULTS: APOS was found in 326 patients (33%), and these
patients had decreased 5-year OS compared with ANEG (65% vs. 77%,
p<0.001). They also demonstrated reduced SRF at 5 years (72% vs.
86%, p<0.001). However, significant differences in OS based on pro-
teinuria were only observed in the G1, G2, and G3a groups, and dif-
ferences in SRF in G3a. On multivariable analysis for all patients or
those with G1/G2/G3a, proteinuria was an independent prognosticator
for OS(both p< 0.05). On multivariable analysis for all patients or those
with G3a, proteinuria was an independent prognosticator for decreasedSRF(both p< 0.05). Limitations include retrospective design and po-
tential ascertainment bias.
CONCLUSIONS: Proteinuria appears to be a significant and
independent predictor of decreased OS and SRF in patients undergoing
renal cancer surgery, particularly certain cohorts, and should be
sensibly incorporated into routine clinical management. Further studies,
ideally prospective, will be required to evaluate the importance of de-
gree of proteinuria, and the generalizability of our findings.
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INTRODUCTION AND OBJECTIVES: Tuberous Sclerosis (TS)
is a genetic, multisystem disorder characterized by the growth of
widespread hamartomas in multiple organs. Patients with TS can
develop renal cysts, renal cell carcinoma, and angiomyolipomas
(AMLs). Up to 80% of TS patients will have at least one AML in their
lifetime. AMLs have the potential to increase in size over time, with
lesions >4cm at increased risk of spontaneous, and possibly life-
threatening, retroperitoneal hemorrhage. In this study we aim to
describe the incidence and natural history of AMLs in a population of
children and adolescents with TS, and utilize AML tumor kinetic
modeling to determine optimal renal imaging intervals in an effort to
improve urologic counseling, follow-up, and treatment.
METHODS: We performed an IRB approved, retrospective
chart review of all patients managed in our pediatric and adolescent
multidisciplinary TS clinic from 2004-2014. Data collected for each pa-
tient included: demographics, renal function, extra-renal manifestations,
renal imaging, genetic testing, mTOR inhibitors, and surgical
interventions.
RESULTS: A total of 145 patients were analyzed. Median age
was 11yr (range 2-28). 94% underwent renal surveillance with ultra-
sound, 4.8% CT, and 0.7% MRI. Overall AML incidence was 50.3%.
Median age at first AML was 11yr (2-26). Median size of AML at first
detection was 0.7cm (0.5-6.7). AML growth rate stratified by age at first
AML: age 0-6yr (0.9 mm/yr), 7-11 (1.0), 12-16 (3.7), and 17+ (33.2).
AML growth rate stratified by AML size at first detection: 0.6-0.9cm (1.6
mm/yr), 1.0-1.9 (10.5), 2.0-2.9 (26.1). Figure 1 displays AML growth
velocity based on patient age and AML size. Thirty-five patients (18.1%)
were treated with mTOR inhibitors. Eight patients underwent a total of
13 interventions (embolization, biopsy, partial or total nephrectomy), of
which two were previously treated with mTOR inhibitors. Mean patient
age and AML size at time of intervention was 18.7yr and 5.2cm,
respectively.
CONCLUSIONS: This is the largest institutional series to date
of renal AMLs in pediatric and adolescent TS patients. Growth of AMLs
in this specific TS population can be rapid and unpredictable. We
recommend annual renal ultrasounds in all TS patients of all ages, with
consideration of MRI in patients at higher risk for rapid growth (>11
years of age and/or AML > 2cm in size).
